Program
Psilocybin
Also written as “PEX010-Assisted Therapy”, “COMP360 psilocybin” and “Psilocybin therapy”.
Its studies are mostly in Depressive Disorder, Treatment-Resistant · Stress Disorders, Post-Traumatic · Combat Disorders · Adjustment Disorders · Depressive Disorder, Major, led by 12 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| COMPASS Pathways | 83 open or running | phase 3since Nov 14, 2022 | Dec 11, 2018 | Nov 2028phase 3 · NCT07570654 |
| MycoMedica Life Sciences PBC | 30 open or running | phase 1since Mar 5, 2024 | Mar 5, 2024 | none ahead |
| Filament Health | 22 open or running | phase 2since Sep 19, 2024 | Sep 19, 2024 | Dec 2026phase 2 · NCT06608459 |
| Apex Labs | 11 open or running | phase 2since Nov 8, 2023 | Nov 8, 2023 | none ahead |
| Clairvoyant Therapeutics | 11 open or running | phase 2since Dec 2, 2022 | Dec 2, 2022 | none ahead |
| Cybin Therapeutics | 10 open or running | phase 2since Oct 19, 2022 | Oct 19, 2022 | none ahead |
| Eli Lilly | 10 open or running | phase 1since May 6, 2021 | May 6, 2021 | none ahead |
| Empower Research | 11 open or running | phase 2since Dec 11, 2023 | Dec 11, 2023 | none ahead |
| Halucenex Life Sciences | 11 open or running | phase 2since Dec 15, 2021 | Dec 15, 2021 | none ahead |
| Nova Mentis Life Science | 10 open or running | phase 2since Mar 8, 2023 | Mar 8, 2023 | none ahead |
| optimi-health-corporation | 10 open or running | early phase 1since Jan 27, 2022 | Jan 27, 2022 | none ahead |
| Psyence Australia Pty | 11 open or running | phase 2since Feb 12, 2025 | Feb 12, 2025 | Mar 30, 2027phase 2 · NCT07072728 |
Also a collaborator on its studies: optimapharm, mitacs and KGK Science.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 8 studies since Dec 11, 2018.
- Nov 14, 2022Phase 3 study in Depressive Disorder, Treatment-ResistantCOMPASS Pathways · NCT05624268 · 258 enrolled · United States
- Dec 2, 2022Clairvoyant Therapeutics's first study: phase 2 study in AlcoholismNew to Clairvoyant TherapeuticsClairvoyant Therapeutics · NCT05646303 · 128 enrolled · Canada, Finland
- Jan 25, 2023Phase 3 study in Depressive Disorder, Treatment-ResistantCOMPASS Pathways · NCT05711940 · 572 enrolled · United States, Canada, Czechia and more
- Feb 8, 2023Phase 2 study in Depressive Disorder, MajorCOMPASS Pathways · NCT05733546 · 102 enrolled · United States
- Mar 8, 2023Nova Mentis Life Science's first study: phase 2 study in Fragile X SyndromeNew to Nova Mentis Life ScienceNova Mentis Life Science · NCT05832255 · 10 enrolled · Canada
- Nov 8, 2023Apex Labs's first study: phase 2 study in Stress Disorders, Post-TraumaticNew to Apex LabsApex Labs · NCT06141876 · 160 planned
- Dec 11, 2023Empower Research's first study: phase 2 study in PsilocybinNew to Empower ResearchEmpower Research · NCT06471959 · 32 planned · Canada
- Mar 5, 2024MycoMedica Life Sciences PBC's first study: phase 1 study in Healthy VolunteersNew to MycoMedica Life Sciences PBCMycoMedica Life Sciences PBC · NCT06326606 · 24 enrolled · Australia
- Sep 19, 2024Filament Health's first study: phase 2 study in Opioid-Related DisordersNew to Filament HealthFilament Health · NCT06608459 · 10 planned
- Oct 10, 2024Phase 1 study in Healthy VolunteersMycoMedica Life Sciences PBC · NCT06643637 · 16 enrolled · Australia
- Oct 29, 2024Phase 2 study in Stimulant Use DisorderFilament Health · NCT06666010 · 86 planned
- Feb 12, 2025Psyence Australia Pty's first study: phase 2 study in Adjustment DisordersNew to Psyence Australia PtyPsyence Australia Pty · NCT07072728 · 87 planned · Australia
- Jun 16, 2025Phase 1 study in Healthy VolunteerMycoMedica Life Sciences PBC · NCT07050368 · 20 enrolled · United Kingdom
- Apr 30, 2026Phase 3 study in Combat DisordersCOMPASS Pathways · NCT07570654 · 300 planned · United States, Canada
Ahead
- Dec 2026Primary completion: phase 2 study in Opioid-Related DisordersFilament Health · NCT06608459
- Mar 30, 2027Primary completion: phase 2 study in Adjustment DisordersPsyence Australia Pty · NCT07072728
- Jan 2028Primary completion: phase 2 study in Stimulant Use DisorderFilament Health · NCT06666010
- Nov 2028Primary completion: phase 3 study in Combat DisordersCOMPASS Pathways · NCT07570654
TargetBeta
“Serotonin 2a (5-HT2a) receptor agonist”ChEMBL 37, by rule
Other programs on HTR2A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Aripiprazolerule | Otsuka | phase 4 | 131 |
| Risperidonerule | Johnson & Johnson | phase 4 | 111 |
| paliperidonerule | Johnson & Johnson | phase 4 | 106 |
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
| brexpiprazolerule | Otsuka | phase 4 | 70 |
| lurasidonerule | Sumitomo Pharma | phase 4 | 52 |
| cyclobenzaprinerule | Tonix Pharmaceuticals | phase 4 | 32 |
| iloperidonerule | Vanda Pharmaceuticals | phase 4 | 15 |
| lumateperonerule | Johnson & Johnson | phase 3 | 25 |
| Trazodonerule | Angelini Pharma | phase 3 | 14 |
| bretisilocin | AbbVie | phase 2 | 1 |
| bretisilocin | AbbVie | phase 1 | 1 |
Studies
All 22 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07570654Combat Disorders · United States, Canada | 3 | Recruiting | COMPASS Pathways | Nov 2028 | 300 |
| NCT07050368Healthy Volunteer · United Kingdom | 1 | Completed | MycoMedica Life Sciences PBC | Jan 13, 2026 | 20 |
| NCT07072728Adjustment Disorders · Australia | 2 | Recruiting | Psyence Australia Pty | Mar 30, 2027 | 87 |
| NCT06666010Stimulant Use Disorder | 2 | Not yet recruiting | Filament Health | Jan 2028 | 86 |
| NCT06643637Healthy Volunteers · Australia | 1 | Completed | MycoMedica Life Sciences PBC | Mar 12, 2025 | 16 |
| NCT06608459Opioid-Related Disorders | 2 | Not yet recruiting | Filament Health | Dec 2026 | 10 |
| NCT06326606Healthy Volunteers · Australia | 1 | Completed | MycoMedica Life Sciences PBC | Jul 8, 2024 | 24 |
| NCT06471959Psilocybin · Canada | 2 | Recruiting | Empower Research | Jul 1, 2025 | 32 |
| NCT06141876Stress Disorders, Post-Traumatic | 2 | Not yet recruiting | Apex Labs | Jun 15, 2025 | 160 |
| NCT05832255Fragile X Syndrome · Canada | 2 | Suspended | Nova Mentis Life Science | May 2024 | 10 |
| NCT05733546Depressive Disorder, Major · United States | 2 | Active, not recruiting | COMPASS Pathways | Sep 2025 | 102 |
| NCT05711940Depressive Disorder, Treatment-Resistant · United States, Canada, Czechia and more | 3 | Active, not recruiting | COMPASS Pathways | Nov 13, 2025 | 572 |
| NCT05646303Alcoholism · Canada, Finland | 2 | Active, not recruiting | Clairvoyant Therapeutics | Aug 31, 2024 | 128 |
| NCT05624268Depressive Disorder, Treatment-Resistant · United States | 3 | Completed | COMPASS Pathways | May 28, 2025 | 258 |
| NCT05594667Depression · Canada | 2 | Withdrawn | Cybin Therapeutics | Mar 14, 2023 | 0 |
| NCT05481736Anorexia Nervosa · United States, Ireland, United Kingdom | 2 | Completed | COMPASS Pathways | Nov 18, 2024 | 32 |
| NCT05312151Stress Disorders, Post-Traumatic · United States, United Kingdom | 2 | Completed | COMPASS Pathways | Feb 12, 2024 | 22 |
| NCT05252598Parasomnias | Early 1 | Withdrawn | optimi-health-corporation | Aug 2023 | 0 |
| NCT05243329Stress Disorders, Post-Traumatic · Canada | 2 | Active, not recruiting | Halucenex Life Sciences | Oct 30, 2023 | 20 |
| NCT04905121Short Lasting Unilateral Neuralgiform Headache Attacks · United Kingdom | 1 | Terminated | Eli Lilly | Apr 22, 2022 | 4 |
| NCT04739865Depressive Disorder, Treatment-Resistant · United States, Ireland | 2 | Completed | COMPASS Pathways | Oct 14, 2021 | 19 |
| NCT03775200Depressive Disorder, Treatment-Resistant · United States, Canada, Czechia and more | 2 | Completed | COMPASS Pathways | Jul 30, 2021 | 233 |
How it is read
Names in the registry
- “Psilocybin”, 16 entries
- “PEX010-Assisted Therapy”, 2 entries
- “COMP360 psilocybin”, 1 entry
- “Psilocybin therapy”, 1 entry
- “Psilocybin, 1.5 mg”, 1 entry
Codes read as this program: PEX010.
Conditions, from the studies’ own filings
- Depressive Disorder, Treatment-Resistant, 4 studies
- Stress Disorders, Post-Traumatic, 3 studies
- Combat Disorders, 1 study
- Adjustment Disorders, 1 study
- Depressive Disorder, Major, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.